Aluminum Oxide Ambergris Barium Carbonate Chaste T
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aluminum Oxide Ambergris Barium Carbonate Chaste T
- Multi-Ingredient Homeopathic Complex (20 Components): No TxGNN Predictions Available – Evaluation Cannot Proceed
Multi-Ingredient Homeopathic Complex (20 Components): No TxGNN Predictions Available – Evaluation Cannot Proceed
One-Sentence Summary
This Evidence Pack describes a 20-ingredient combination product containing homeopathic-class components such as Conium maculatum, Helleborus niger, Lycopodium clavatum, Cicuta virosa, and Sus scrofa cerebrum, among others. The product holds no market authorization in Taiwan or the United States, and the TxGNN pipeline did not generate any predicted new indications for this entry. Without a candidate disease target or an established original indication, a standard drug repurposing evaluation cannot be completed at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available |
| Predicted New Indication | No TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | Unable to assess — no prediction generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
The ingredient string submitted to the pipeline consists of 20 chemically and botanically diverse substances:
Aluminum Oxide · Ambergris · Barium Carbonate · Chaste Tree Fruit · Cicuta virosa Root · Conium maculatum Flowering Top · Cupric Acetate · Dibasic Potassium Phosphate · Ginkgo · Helleborus niger Root · Lead · Lycopodium clavatum Spore · Phosphoric Acid · Picric Acid · Selenium · Semecarpus anacardium Juice · Silver Nitrate · Sus scrofa Cerebrum · Thiamine Hydrochloride · Zinc
This composition is characteristic of a homeopathic combination product, where each ingredient is typically present at highly diluted potency. The TxGNN knowledge graph is built on single-entity DrugBank nodes; a 20-component homeopathic mixture cannot be mapped to a single DrugBank ID, which is why the pipeline returned no candidate and no score.
No mechanism of action data is available, and no original approved indication is registered in any regulatory database queried. As a result, the mechanistic reasoning section that would normally appear here cannot be written.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
This product holds no US market authorization. No NDA records were retrieved.
Safety Considerations
Several ingredients in this combination carry intrinsic toxicological concern at non-homeopathic doses:
- Cicuta virosa (water hemlock) and Conium maculatum (poison hemlock) are acutely neurotoxic plants.
- Lead and Silver Nitrate are heavy metal/oxidizing agents with well-documented systemic toxicity.
- Picric Acid is a reactive compound with hepatotoxic and nephrotoxic potential.
Whether these risks are clinically relevant depends entirely on the actual potency (dilution level) of the finished product, which is not documented in this Evidence Pack. Please refer to the applicable package insert or product monograph for formulation-specific safety information before any clinical or regulatory assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline could not process this entry as a single drug entity, resulting in zero predicted indications. Without a candidate disease target and without confirmed original approved indications, there is no basis on which to evaluate repurposing potential.
To proceed, the following is needed:
- Clarify the product identity — Determine whether this is a registered homeopathic product with a formal product name (e.g., an OTC homeopathic brand). Search FDA homeopathic drug registries or the HMDB for the combination.
- Identify the lead active ingredient — If the intent is repurposing analysis, select one pharmacologically active component (e.g., Ginkgo, Thiamine, or a specific mineral salt) and run TxGNN on that single entity.
- Obtain the original indication — Retrieve the approved or traditional indication from the product label or regulatory filing to establish the clinical starting point.
- Resolve MOA data gap — Query DrugBank for each individual ingredient to determine which components have documented mechanisms of action.
- Assess formulation potency — Confirm dilution levels for toxic ingredients (Conium, Cicuta, Lead, Silver Nitrate, Picric Acid) before any safety evaluation can be completed.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.